At the start of the genomics era when the first human genome became available, it was thought that knowing our DNA code would provide sufficient biomarkers to get us a good way toward our precision medicine goal. Unfortunately, the underlying complexity of the genome (and epigenome) proved to be far more intractable than many researchers expected. It soon became clear that genomics was not the panacea we sought, but required complementation from other'omics, including (but not limited to) proteomics, metabolomics, and transcriptomics. We are now at the point where genomics discovery tools (mostly high-throughput, rapid-sequencing technologies) are reaching maturity, while proteomics and other technologies are on the upswing. The articles in this booklet describe recent advances in proteomics technologies and how they are enabling the identification of new biomarkers that researchers are optimistic will advance us well along the track to realizing our objective for precision medicine. Much work remains to be done, but there is little doubt that the wind is at our backs and the scientific discoveries coming out of this multi-omics era will benefit patients in measurable ways.